Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Efficacy and Safety of Subcutaneous Spesolimab for the Prevention of Generalised Pustular Psoriasis Flares (Effisayil 2): an International, Multicentre, Randomised, Placebo-Controlled Trial : Episode 5

Opinion

Video

December 16, 2024

Demographics and Baseline Characteristics Across Spesolimab Dose Groups

Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.

EP: 1.Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

EP: 2.Study Objectives and Key Inclusion Criteria for GPP Patients

EP: 3.Spesolimab Dosing Regimens

EP: 4.Primary and Secondary Endpoints

Now Viewing

Demographics and Baseline Characteristics Across Spesolimab Dose Groups

EP: 1.Revolutionizing GPP Management: The Efficacy and Safety of Spesolimab in Preventing Life-Threatening Flares

EP: 2.Study Objectives and Key Inclusion Criteria for GPP Patients

EP: 3.Spesolimab Dosing Regimens

EP: 4.Primary and Secondary Endpoints

EP: 5.Demographics and Baseline Characteristics Across Spesolimab Dose Groups

EP: 6.Spesolimab Efficacy Data